MDxHealth
MDxHealth's revenue rose 19.8% to $108 million in fiscal 2025. Its operating margin was −13.4%, up from −27.4% a year earlier. Free cash flow was −$3 million. The diluted share count rose 52.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
MDxHealth lost money in fiscal 2025: a net loss of $34 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 58 | 16 | 22 | 47 | 29 |
| Debt incl. finance leases | — | — | 36 | 51 | 76 |
| Net debt (negative means net cash) | — | — | 14 | 4 | 47 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 5.0x | 3.5x | — |
| Interest coverage | −117.2x | −120.7x | −77.0x | −64.4x | −18.3x |
| Current ratio | 4.0x | 1.6x | 1.9x | 1.6x | 1.1x |
| Quick ratio | 3.9x | 1.5x | 1.8x | 1.5x | 0.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 3 of 9 |
| Rule of 40 | 54.9% | 6.4% | 16.7% |
| Altman Z'' | −8.78 | −7.59 | −9.44 |
| Accruals ratio | −17.4% | −13.6% | −20.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | 3 of 9 | 3 of 9 |
Compare
Put MDxHealth side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MDxHealth | FY25 | 19.8% | −13.4% | −3.1% | −41.8% | — | 3 | |
| Biodesix | FY25 | 24.1% | −31.5% | −26.6% | −69.7% | — | 3 | Compare |
| Ridgetech | FY26 | 10.2% | −1.4% | −1.1% | — | — | — | Compare |
| Grail | FY25 | 17.2% | −382.0% | −203.8% | — | — | — | Compare |
| AirSculpt Technologies | FY25 | −15.8% | −7.6% | 0.5% | −6.6% | 39.0x | 3 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 12 | 18 | 22 | 37 | 70 | 90 | 108 |
| Revenue growth | — | 56.6% | 20.5% | 66.6% | 89.4% | 28.3% | 19.8% |
| Gross profit | 0 | 8 | 11 | 19 | 44 | 55 | 70 |
| Research and development | 9 | 4 | 6 | 6 | 6 | 11 | 10 |
| Operating income | −43 | −27 | −27 | −38 | −27 | −25 | −14 |
| Net income | −43 | −29 | −29 | −44 | −43 | −38 | −34 |
| Diluted EPS (US$) | −6.90 | — | — | −2.78 | −1.66 | −1.16 | −0.67 |
| Diluted shares (millions) | 0 | 8 | 12 | 16 | 26 | 33 | 50 |
| Cash flow | |||||||
| Cash from operations | −22 | −20 | −22 | −34 | −22 | −18 | −2 |
| Capital expenditure | 0 | 0 | 1 | 3 | 3 | 1 | 1 |
| Free cash flow | −22 | −21 | −23 | −37 | −24 | −20 | −3 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 16 | 58 | 16 | 22 | 47 | 29 |
| Debt incl. finance leases | — | — | — | — | 36 | 51 | 76 |
| Total assets | — | 32 | 75 | 119 | 129 | 157 | 148 |
| Total liabilities | — | 26 | 28 | 110 | 122 | 142 | 160 |
| Shareholders' equity | 20 | 6 | 47 | 9 | 7 | 15 | −12 |
| Margins and ratios | |||||||
| Gross margin | 0.2% | 43.6% | 47.5% | 51.9% | 62.6% | 61.2% | 64.5% |
| Operating margin | −366.3% | −146.9% | −120.7% | −102.3% | −38.9% | −27.4% | −13.4% |
| Net margin | −365.7% | −155.3% | −130.4% | −118.9% | −61.4% | −42.3% | −31.1% |
| Free cash flow margin | −189.8% | −112.6% | −105.4% | −99.6% | −34.5% | −21.9% | −3.1% |
| Rule of 40 (growth + FCF margin) | — | −55.9% | −85.0% | −33.0% | 54.9% | 6.4% | 16.7% |
| Return on capital | — | — | — | — | — | −96.8% | −41.8% |
| Return on equity | — | — | −110.0% | −156.7% | −521.7% | −345.3% | — |
| Return on assets | — | — | −54.2% | −45.4% | −34.7% | −26.6% | −22.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |